Inhalable microparticles containing large payload of anti-tuberculosis drugs.
about
Revealing facts behind spray dried solid dispersion technology used for solubility enhancementTreatment of Mycobacterium tuberculosis-Infected Macrophages with Poly(Lactic-Co-Glycolic Acid) Microparticles Drives NFκB and Autophagy Dependent Bacillary KillingAntifungal Activity of Amphotericin B Conjugated to Nanosized Magnetite in the Treatment of ParacoccidioidomycosisSystems Pharmacology Approach Toward the Design of Inhaled Formulations of Rifampicin and Isoniazid for Treatment of TuberculosisInhaled antibiotics for lower airway infections.Preparation and characterization of beta-glucan particles containing a payload of nanoembedded rifabutin for enhanced targeted delivery to macrophages.Expression Profile of Markers of Apoptosis, Injury and Oxidative Stress in Human Lung Epithelium Cells-A5449 Receiving Chronic Exposure of Potential Anti-Tubercular Drug-trans-Cyclohexane-1, 4-Diamine Derivative-"9u".An update on the use of rifapentine for tuberculosis therapy.Rifapentine-proliposomes for inhalation: in vitro and in vivo toxicity.Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticlesMouse model for efficacy testing of antituberculosis agents via intrapulmonary deliveryControlled-release approaches towards the chemotherapy of tuberculosis.Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.Interactions of nanoparticles with pulmonary structures and cellular responses.Fighting tuberculosis: old drugs, new formulations.Preclinical models for pulmonary drug delivery.Micro- and nanocarrier-mediated lung targeting.Advances in pulmonary delivery of nanoparticles.Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases.Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.Pharmaceutical aerosols for the treatment and prevention of tuberculosisMechanisms of absorption and elimination of drugs administered by inhalation.Nanoparticle-mediated pulmonary drug delivery: a reviewThe role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy.Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for h. PyloriMacrophage-specific targeting of isoniazid through mannosylated gelatin microspheres.Particles from preformed polymers as carriers for drug delivery.Antibacterial Loaded Spray Dried Chitosan Polyelectrolyte Complexes as Dry Powder Aerosol for the Treatment of Lung InfectionsPulmonary delivery of antitubercular drugs using spray-dried lipid-polymer hybrid nanoparticles.Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage.Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb).Freeze thaw: a simple approach for prediction of optimal cryoprotectant for freeze dryingEnhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity.Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy.Toward an optimized treatment of intracellular bacterial infections: input of nanoparticulate drug delivery systems.Colistin as a potentiator of anti-TB drug activity against Mycobacterium tuberculosis.Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles.Preparation, in vitro characterization, and in vivo pharmacokinetic evaluation of respirable porous microparticles containing rifampicin.Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis.Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats.
P2860
Q26748640-6B166072-5F0F-4C07-9364-22E5C16236EDQ27321663-A0BCD5D2-436A-417A-9607-B4BD72793920Q28550277-6C10EFD4-6D7A-4CE6-A022-644EB94C13C8Q28649769-EAA1295F-450C-4310-A6D9-C627EC40B4FBQ33640488-C28C6F53-D8C7-48D5-A20A-C915DD609435Q33667215-738A78A2-C0BC-4EC3-AF23-222B52DB1D6FQ34221391-68093899-543E-4D3E-95B6-24EA9BFE3E5FQ35084363-64B5D47D-EB75-4DF2-9661-BF89040FC21AQ35549569-B4BC6B6B-9BC6-4BE3-B146-B10F7E2F95D0Q35941391-DCB4741D-5C72-45E3-8002-4393B2EB845AQ36086381-280D43A2-082F-4FA3-8B6B-41E35854319AQ36321657-EB4EC73C-D0BA-4DCA-B47F-6B1BC6B169F8Q36870723-560E26A0-C5FE-47D9-AD64-8DEF6A0EF1B0Q37080749-64BAD82C-442F-4274-8C77-A6CCA0D3529FQ37579212-F07E63A7-6809-4B36-A732-4946842679B3Q37620365-BAE8B4DC-4408-4EB5-BE46-FA5EDADCE941Q37766234-AD0EE539-24A1-4D1A-A52C-C0E8E27E6FE3Q37909465-684BA39C-39AC-4FBD-A557-F9B989BCC7B4Q37976848-D9AF0D52-9966-40C2-8A93-356B8CC3EEA7Q37978509-C361DA4C-A204-46FA-BD2C-BAC8A46EB888Q38042953-D0412BD8-AD4E-4925-9039-0A97EB5C2A1AQ38126941-48EB64E5-6165-4AF7-9C51-FE53795FF6FFQ38203377-6E718A08-C162-48EA-956D-000DA51F675BQ38236719-D7914514-897D-4ACE-8E84-E4FC37233C70Q38268630-A96DF5D0-FC7B-44E5-B28B-57B7F9B4742EQ38311993-36F08F5C-A0DF-467E-B6BB-E7EB45195534Q38594961-805F20B5-499C-4434-9ADA-81838035CCA6Q38703794-9A27D931-A54B-43CC-B05A-83A89B83002FQ38852563-9D87DDEF-5D29-42E5-B6E8-42FE089F27C5Q39102887-98723D4A-7DF6-431D-B17C-DC879B757B98Q39425428-88E847E9-09F5-40CE-B0CA-ACA9104A9404Q39923763-11FB2476-5078-41FC-BCE7-3FB785C5CA11Q40100391-643ADCC1-1BE9-4581-9753-CF59BA26CB60Q40707446-D8CF7986-66D6-4609-A458-6C84DD023494Q40974806-BE6C2D18-7BFE-4014-B5D3-CCC6E26E2356Q41104455-3CF06038-F7E7-486D-87ED-1C9B9534860EQ41989537-836BD84C-492F-409A-A4FF-0A8D88F99C6BQ42148661-37021055-BE7B-4876-86C9-267D955A26EEQ42227059-3546C866-86A7-4A07-BAE4-7279412C8966Q42241235-829A550F-2255-4DBE-9C81-7FC970C85D34
P2860
Inhalable microparticles containing large payload of anti-tuberculosis drugs.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Inhalable microparticles containing large payload of anti-tuberculosis drugs.
@ast
Inhalable microparticles containing large payload of anti-tuberculosis drugs.
@en
type
label
Inhalable microparticles containing large payload of anti-tuberculosis drugs.
@ast
Inhalable microparticles containing large payload of anti-tuberculosis drugs.
@en
prefLabel
Inhalable microparticles containing large payload of anti-tuberculosis drugs.
@ast
Inhalable microparticles containing large payload of anti-tuberculosis drugs.
@en
P2093
P1476
Inhalable microparticles containing large payload of anti-tuberculosis drugs.
@en
P2093
Amit Misra
Awadh Bihari Yadav
Jatinder Kaur
Kaushlendra Kumar
Pavan Muttil
Rolee Sharma
P304
P356
10.1016/J.EJPS.2007.06.006
P407
P577
2007-07-04T00:00:00Z